仙乐健康启动赴港上市:业绩“外热内冷” 拟剥离子公司“瘦身”

Core Viewpoint - The company is initiating a plan to issue H-shares and list on the Hong Kong Stock Exchange, driven by a significant divergence in revenue growth between its domestic and international businesses, with international operations becoming the main growth engine while domestic operations face challenges [3][4]. Group 1: Financial Performance - In 2024, the company's international business revenue grew by 47.33% to 2.55 billion yuan, accounting for over 60% of total revenue, while domestic revenue declined by 10.28% [2][4]. - For the first half of 2025, the company reported total revenue of 2.04 billion yuan, a year-on-year increase of 2.57%, with net profit attributable to shareholders rising by 4.30% to 161 million yuan [4]. - The company's revenue from domestic operations in the first half of 2025 was 818 million yuan, down 1.63%, while international revenue was 1.22 billion yuan, up 5.58% [4]. Group 2: Strategic Initiatives - The company aims to deepen its global strategy and enhance its capital strength through the issuance of H-shares, which is seen as a pragmatic response to the sluggish growth in the domestic market [3][4]. - The company is also seeking investment or divestment opportunities for its subsidiary BFPC, which has been operating at a loss, to improve overall profitability and market competitiveness [9]. Group 3: Business Model and Market Position - The company operates in the CDMO (Contract Development and Manufacturing Organization) sector, providing a full range of services from product development to marketing support [8]. - Since its listing in 2019, the company has shown a trend of increasing revenue from 1.58 billion yuan to 4.21 billion yuan by 2024, with a notable shift in the revenue contribution from domestic to international markets [8].